Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 8,147 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: GI Disorders Clear all
Terminated Phase 1 Interventional

Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression

NCT00444236
View directory record Official record
Conditions
Exercise Triggered Asthma, Gastroesophageal Reflux
Interventions
Nexium, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 2 Interventional

Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach

NCT00004235
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
docetaxel, irinotecan hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
18
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery

NCT00290615
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, cetuximab, capecitabine, oxaliplatin
Biological · Drug
Lead sponsor
Herbert Hurwitz
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Durham, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Oct 25, 2026, 4:15 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative Colitis

NCT07749768
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
ONO-6414, Placebo
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 25, 2026, 4:15 AM EDT
Completed No phase listed Observational Results available

Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey

NCT04317690
View directory record Official record
Conditions
High Cholesterol, High Blood Pressure, Colorectal Cancer, Breast Cancer, Prostate Cancer
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 75 Years
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 25, 2026, 4:15 AM EDT
Terminated Phase 4 Interventional Results available

Trial of High Dose Vitamin D in Patient's With Crohn's Disease

NCT02208310
View directory record Official record
Conditions
Crohn's Disease, Vitamin D Deficiency
Interventions
Cholecalciferol 10,000 IU, Cholecalciferol 400 IU
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Indianapolis, Indiana • Iowa City, Iowa • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 25, 2026, 4:15 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Dose-finding IMU-838 for Ulcerative Colitis

NCT03341962
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
IMU-838, Placebo
Drug
Lead sponsor
Immunic AG
Industry
Eligibility
18 Years to 80 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • Ventura, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma

NCT00737438
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Not applicable Interventional

Effects of Low FODMAP Diet on Leaky Gut

NCT04526808
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
FODMAP diet
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 25, 2026, 4:15 AM EDT
Terminated Phase 2 Interventional Results available

Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery

NCT00493025
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, gefitinib, paclitaxel, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 25, 2026, 4:15 AM EDT
Recruiting No phase listed Observational

Cricopharyngeal Dysfunction and Esophageal Diverticulum

NCT03187925
View directory record Official record
Conditions
Zenker Diverticulum, Progressive Dysphagia, Pharyngoesophageal Diverticulum
Interventions
open, transcervical versus rigid endoscopic treatment
Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 100 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 25, 2026, 4:15 AM EDT
Terminated Phase 4 Interventional Results available

Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices

NCT03624517
View directory record Official record
Conditions
Esophageal Varices, Liver Cirrhoses, Bleeding Esophageal Varices, Upper Gastrointestinal Bleeding
Interventions
Octreotide
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
Jacksonville, Florida • Chicago, Illinois • Columbus, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease

NCT00847210
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Dexlansoprazole MR
Drug
Lead sponsor
Takeda
Industry
Eligibility
12 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Anaheim, California • Cypress, California • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 2Phase 3 Interventional

Adjunctive Neuromuscular Electrical Stimulation for the Rehabilitation of Swallowing

NCT01279824
View directory record Official record
Conditions
Dysphagia
Interventions
swallowing therapy
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 90 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Oct 25, 2026, 4:15 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

NCT05583149
View directory record Official record
Conditions
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL), De Novo or Transformed Indolent B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, T Cell/Histiocyte-rich Large B-cell Lymphoma, EBV-Positive DLBCL, Nos, Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma, Nos, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, Grade 3b Follicular Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
Interventions
ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy
Drug
Lead sponsor
Patrick C. Johnson, MD
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 25, 2026, 4:15 AM EDT
Withdrawn Phase 4 Interventional

Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis

NCT01326117
View directory record Official record
Conditions
Gastroparesis, Diabetic Gastroparesis, Nausea, Vomiting
Interventions
tadalafil
Drug
Lead sponsor
Mark Feinglos
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Oct 25, 2026, 4:15 AM EDT
Withdrawn No phase listed Observational

Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples

NCT01792882
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Hematologic Cancer
Interventions
Not listed
Lead sponsor
Global BioClinical
Industry
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 25, 2026, 4:15 AM EDT
Recruiting No phase listed Observational

Effect of Thickened Feeds on Clinical Outcomes in Children With Brief Resolved Unexplained Event

NCT04477460
View directory record Official record
Conditions
Brief Resolved Unexplained Event, Apparent Life Threatening Event, Oropharyngeal Dysphagia
Interventions
Thickened feeds, Non-thickened feeds
Dietary Supplement
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Months to 12 Months
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 25, 2026, 4:15 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

NCT02298959
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Renal Cell Carcinoma, Platinum-Resistant Ovarian Carcinoma, Recurrent Melanoma, Recurrent Renal Cell Carcinoma, Refractory Melanoma, Refractory Renal Cell Carcinoma, Sarcoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Pembrolizumab, Ziv-Aflibercept
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
7
States / cities
Tampa, Florida • Bethesda, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 25, 2026, 4:15 AM EDT
Terminated Phase 1 Interventional

A Study of SGN-CD228A in Advanced Solid Tumors

NCT04042480
View directory record Official record
Conditions
Cutaneous Melanoma, Pleural Mesothelioma, HER2 Negative Breast Neoplasms, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
SGN-CD228A
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 25, 2026, 4:15 AM EDT
Completed No phase listed Observational

Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors

NCT01987726
View directory record Official record
Conditions
Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Breast Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
cytology specimen collection procedure, laboratory biomarker analysis
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Not applicable Interventional Results available

Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer

NCT00253708
View directory record Official record
Conditions
Cancer
Interventions
management of therapy complications, massage therapy, pain therapy, psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 25, 2026, 4:15 AM EDT
Terminated Not applicable Interventional Results available

Acupuncture in Reducing the Severity of Chemoradiation-induced Mucositis in Patients With Oropharyngeal Cancer

NCT01883908
View directory record Official record
Conditions
Mucositis, Oropharyngeal Cancer
Interventions
Acupuncture with Seirin® needles, Usual medical care
Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 25, 2026, 4:15 AM EDT
Terminated Phase 2 Interventional Results available

Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy

NCT04456517
View directory record Official record
Conditions
Crohn's Disease, Inflammatory Bowel Disease
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 25, 2026, 4:15 AM EDT